Vivimed Labs Q2 FY2023 consolidated loss at Rs. 22.03 Cr
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
The company has reported total income of Rs. 44.37 crores during the period ended September 30, 2022
The product is expected to be launched by Q4 FY23.
Strand’s new offering will help people better understand and manage diseases through genomic sequencing
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
Cadila Pharmaceuticals was felicitated during the plenary session of the 21st International Leprosy Congress
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
The company is focussed on increasing the capacity utilizations while controlling costs
The company sees the business reaching $100mn
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
Subscribe To Our Newsletter & Stay Updated